Articles tagged "Rejection"

2017 American Transplant Congress
Donor Macrophage Depletion from CMV-Latently Infected Hearts Abrogates CMV-Accelerated Chronic Rejection.
J. Burg,¹ T. Andoh,² N. Haese,² I. Jones,² S. Orloff,¹ D. Streblow.²
¹Department of Surgery, OHSU, Portland, OR; ²VGTI, OHSU, Hillsboro, OR
Purpose: Latent donor CMV infection has been shown to accelerate chronic rejection (CR) in a heterotopic rat heart transplant model. CMV latency is associated with…
2017 American Transplant Congress
Donor-Derived Cell-Free DNA Normal Range and Biological Variation Defined in a Reference Population.
J. Bromberg,¹ D. Brennan,² E. Poggio,³ D. Hiller,⁴ R. Woodward,⁴ J. Yee,⁴ J. Sninsky,⁴ R. Bloom.⁵
¹University of Maryland, Baltimiore, MD; ²Washington University, St. Louis, MO; ³Cleveland Clinic, Cleveland, OH; ⁴CareDx, Brisbane, CA; ⁵University of Pennsylvania, Philadelphia, PA
Purpose: Donor-derived cell-free DNA (dd-cfDNA) in the circulating blood of transplant recipients has shown promise as a non-invasive biomarker of acute rejection. This analysis was…
2017 American Transplant Congress
Ornithine Transcarbamylase Deficiency (OTC) in the Donor Liver, the Importance of Ascertaining the Cause of Death in the Brain Dead Donor.
M. George,¹ G. Thomas,¹ A. Shun,¹ M. Stormon.²
¹Paediatric Surgery and Transplant Surgery, Children's Hospital at Westmead, Sydney, NSW, Australia; ²Paediatric Gastroenterology, Children's Hospital at Westmead, Sydney, NSW, Australia
The importance of ascertaining the cause of brain death in the donor is vital . We present a case of cadaveric liver donation (seg 2…
2017 American Transplant Congress
Subpopulations of Peripheral Blood Monocytes in Kidney Allograft Recipients.
I. Striz,¹ V. Svachova,¹ A. Sekerkova,¹ J. Slatinska,² K. Kopecka,¹ M. Fialova,¹ O. Viklicky.²
¹Department of Clinical and Transplant Immunology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic; ²Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
Human peripheral blood monocytes may be divided into different subsets based on the expression of membrane antigens. Our pilot data suggested that after the kidney…
2017 American Transplant Congress
Assessment of C4d Positive Biopsies with No Histological Evidence of Inflammation Using Nanostring nCounter Technology.
K. Dominy,¹ M. Willicombe,³ T. Al Johani,² J. Galliford,³ A. McLean,³ T. Cook,³ C. Roufosse.³
¹Centre for Complement and Inflammation Research, Imperial College, London, United Kingdom; ²King Saud University, Riyadh, Saudi Arabia; ³Imperial College Healthcare NHS Trust, London, United Kingdom
Deposition of C4d has been an established part of the Banff classification scheme for antibody mediated rejection (AbMR) since 2001. More recently, C4d negative AbMR…
2017 American Transplant Congress
The IL6/Th17 Pathway May Play Different Roles in Cell-Mediated and Antibody-Mediated Alloimmune Injury in Renal Allografts.
D. Dobi,¹ Q. Tang,² S. Chandran,³ F. Vincenti,³ Z. Laszik.¹
¹Department of Pathology, University of California, San Francisco, San Francisco, CA; ²Department of Surgery, Division of Transplant Surgery, University of California, San Francisco, San Francisco, CA; ³Department of Medicine, Division of Nephrology, University of California, San Francisco, San Francisco, CA
Purpose. IL6 has been shown to contribute to shifting the balance between tolerogenic regulatory T cells and proinflammatory Th17 cells towards the latter. Our study…
2017 American Transplant Congress
Adjunctive Thymoglobulin with Proteasome Inhibitor Based Treatment of Late Mixed Acute Rejection.
A. Lichvar,¹ A. Leino,¹ S. Tremblay,¹ A. Shields,² F. Paterno,¹ A. Govil,¹ M. Anand,¹ T. Diwan,¹ J. Kremer,² R. Alloway,¹ E. Woodle.¹
¹University of Cincinnati, Cincinnati; ²The Christ Hospital, Cincinnati
Proteasome inhibitor (PI) containing regimens treat mixed acute rejection (MAR) at least in part due to elimination of donor specific antibody (DSA) and via effects…
2017 American Transplant Congress
Long-Term Outcome of Antibody-Mediated Rejection Due to Pre-Existing vs. De Novo DSA in Kidney Allograft Recipients.
O. Aubert,¹ C. Lefaucheur,¹ S. Higgins,¹ L. Hidalgo,² J. Duong Van Huyen,¹ D. Viglietti,¹ X. Jouven,¹ D. Glotz,¹ P. Halloran,² A. Loupy.¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²ATAGC, Edmonton, Canada
BackgroundAntibody-mediated rejection (ABMR) can occur in patients with pre-existing anti-HLA donor-specific antibodies (DSA) or in patients who develop de novo DSA. However, how these processes…
2017 American Transplant Congress
A Search for a Biomarker Which Predicts Belatacept-Resistant Rejection.
G. de Graav,¹ C. Baan,¹ M. Clahsen-van Groningen,² R. Kraaijeveld,¹ M. Dieterich,¹ W. Verschoor,¹ D. Roelen,³ M. Cadogan,¹ J. van de Wetering,¹ J. van Rosmalen,⁴ W. Weimar,¹ D. Hesselink.¹
¹Internal Medicine, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ²Pathology, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ³Immunohematology and Blood Transfusion, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ⁴Biostatistics, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands
Belatacept, an inhibitor of the CD28-CD80/86 costimulatory pathway, has been associated with a higher acute rejection risk than ciclosporin. We sought to identify a biomarker…
2017 American Transplant Congress
A Non-Invasive Urinary Common Rejection Module (uCRM) Gene Expression Score Quantifies and Differentiates Kidney Transplant Injury.
T. Sigdel,¹ J. Yang,¹ O. Bestard,² S.-C. Hsieh,¹ S. Roedder,² I. Damm,¹ J. Liberto,¹ S. Nandoe,¹ M. Sarwal.¹
¹University of California San Francisco, San Francisco; ²Immucor Inc, Atlanta
We sought to investigate the use of the common rejection module (CRM) genes in the discrimination of AR, BKVN, and stable transplant phenotypes in urine…